Cell and gene therapies are considered highly innovative but also challenging approaches in modern cardiology. While early hopes for adult stem cells from bone marrow or skeletal muscle were largely disappointed, pluripotent stem cells and gene editing methods are now coming into focus. Results from preclinical studies are encouraging, but have not (yet) been confirmed to the same extent in clinical trials. The main problems are immunological issues, arrhythmia risks, costs, lack of reproducibility and, in some cases, ethical concerns. Future developments, including advanced gene editing without double-strand breaks (base/prime editing) or targeted epigenetic modulation, promise to further develop the potential of regenerative medicine in the field of cardiology.
Autoren
- Tanja Schliebe
Publikation
- CARDIOVASC
Related Topics
You May Also Like
- Current status and future prospects
Cell and gene therapies in modern cardiology
- Patient-oriented recommendations for action
Effect of heat on diabetes technology
- Cardiovascular risk and obesity
Pathomechanisms, secondary prevention and treatment options
- Ventricular arrhythmias
Indication for ICD or WCD?
- Early breast cancer
Overweight and obesity worsen the prognosis
- Psoriasis treatment with biologics
What are the latest trends?
- Flu vaccination for older people
Benefit of the high-dose influenza vaccine
- Findings from the ALS Symposium 2024 in Montreal